Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Vito Mario Rapisarda"'
Autor:
Luca Guarnera, Federico Meconi, Marco Pocci, Fabiana Esposito, Manuela Rizzo, Vito Mario Rapisarda, Annagiulia Zizzari, Cosimo Di Raimondo, Livio Pupo, Lucia Anemona, Maria Cantonetti
Publikováno v:
Hematology Reports, Vol 14, Iss 2, Pp 61-66 (2022)
Primary cutaneous CD30+ lymphoproliferative disorders include primary cutaneous anaplastic large cell lymphoma (pcALCL) and lymphomatoid papulosis. The prognosis of the disease is usually excellent but, in a minority of cases, it presents with extrac
Externí odkaz:
https://doaj.org/article/8e7264861f214ae1b26e36f6dd887b6d
Autor:
Luca Guarnera, Federico Meconi, Roberto Secchi, Maria Rosaria Pascale, Fabiana Esposito, Annagiulia Zizzari, Vito Mario Rapisarda, Manuela Rizzo, Livio Pupo, Maria Cantonetti
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 14, Iss 1 (2022)
Introduction Gastric Diffuse large B‐cell lymphoma (DLBCL) is the most common extra-nodal site of lymphoma’s involvement (30%-40% of all extranodal lymphomas and 55%-65% of all gastrointestinal lymphomas). However, gastric localizations are also
Externí odkaz:
https://doaj.org/article/c8949b5e718b4a5fbfe83fd9f88d659f
Autor:
Federico Meconi, Roberto Secchi, Raffaele Palmieri, Sara Vaccarini, Vito Mario Rapisarda, Laura Giannì, Fabiana Esposito, Ida Provenzano, Daniela Nasso, Livio Pupo, Maria Cantonetti
Publikováno v:
Case Reports in Hematology, Vol 2019 (2019)
Primary cutaneous anaplastic large cell lymphoma is a CD-30 positive lymphoproliferative disorder with good prognosis, usually treated with radiation therapy and surgery. Head, neck, and extremities are the most frequently involved sites. In this pap
Externí odkaz:
https://doaj.org/article/2fba72627ab945cc931ccd6aa4a8ef17
Publikováno v:
The American Journal of Dermatopathology. 42:446-451
Primary effusion lymphoma (PEL) is defined as a HHV-8-associated large B-cell lymphoma, which favors HIV-infected young adults, typically presenting as a serous (pleural, pericardial, or peritoneal) effusion with no identifiable tumor mass. Uncommon
Autor:
Maria Ilaria Del Principe, Francesco Buccisano, Vito Mario Rapisarda, Luca Maurillo, Annalisa Biagi, Francesco Lo-Coco, Adriano Venditti, Sergio Amadori, Valentina Rossi, Ambra Di Veroli, William Arcese, Eleonora De Bellis, Annagiulia Zizzari, Maria Teresa Voso
Publikováno v:
Expert Review of Hematology. 11:307-313
Response to therapy is affected by the genetic heterogeneity of acute myeloid leukemia (AML) and persistence of leukemic cells below the threshold of morphological complete remission (mCR). Such persistence is called minimal (or measurable) residual
Autor:
Ambra Di Veroli, Vito Mario Rapisarda, Valentina Rossi, Annalisa Biagi, Maria Ilaria Del Principe, Adriano Venditti, Maria Teresa Voso, Eleonora De Bellis, Francesco Buccisano, Luca Maurillo
Publikováno v:
Journal of Rare Diseases Research & Treatment. 2:41-44
Autor:
G. Paterno, Lucia Anemona, Federico Meconi, Daniela Nasso, Vito Mario Rapisarda, Sara Vaccarini, Maria Cantonetti, Livio Pupo, Fabiana Esposito, Raffaele Palmieri
Publikováno v:
Case Reports in Hematology
Case Reports in Hematology, Vol 2019 (2019)
Case Reports in Hematology, Vol 2019 (2019)
A 74-year-old male with diffuse large B-cell lymphoma, with an Ann Arbor stage IV-A, was submitted to immune-chemotherapy in 2014, with complete remission of the disease. Two years later, he presented with a left eye swelling leading to exophthalmos
Autor:
Luca Franceschini, Emiliano Fabiani, Eleonora De Bellis, Carmelo Gurnari, Vito Mario Rapisarda, Manuela Rizzo, Maria Teresa Voso, Francesco Lo Coco, Diana Postorivo, Paola Panetta, Anna Maria Nardone, Giulia Falconi
The World Health Organization classifies atypical chronic myeloid leukemia (aCML) as a myeloproliferative/myelodisplastic hematological disorder. The primary manifestations are leukocytosis with disgranulopoiesis, absence of basophilia and/or monocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afb00775aa6434f9be82c71fe0a44110
https://europepmc.org/articles/PMC5791424/
https://europepmc.org/articles/PMC5791424/